Pacira BioSciences to Present at the Jefferies London Healthcare Conference
Get Alerts PCRX Hot Sheet
Join SI Premium – FREE
TAMPA, Fla., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference at 11:20 AM GMT (6:20AM ET) on Tuesday, November 16, 2021. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
About Pacira
Pacira BioSciences, Inc. (Nasdaq: PCRX) is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes the company’s unique and proprietary multivesicular liposome delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera°® system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 [email protected]Source: Pacira BioSciences
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- September 2026 Quarterly Results Conference Call
- Palantir Technologies Announces October Seoul Pop-Up with Korea-First Exclusive Merchandise Release
- Jefferies Downgrades Pacira Pharmaceuticals (PCRX) to Hold
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share